SCHEMBL10293197

SCHEMBL10293197

COc1ccc(CNS(=O)(=O)c2ccc3oc(C(=O)NC4CC4)c(C)c3c2)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.75
NPC1 O15118 1/20 0.61
RAB9A P51151 1/20 0.61
TDP1 Q9NUW8 1/20 0.59
GAA P10253 1/20 0.58
HPGD P15428 3/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2D6 P10635 1/20 0.54
CYP2C9 P11712 1/20 0.54
RECQL P46063 1/20 0.54
TP53 P04637 2/20 0.51
CNR1 P21554 2/20 0.51
CNR2 P34972 2/20 0.51
LMNA P02545 1/20 0.50
KDM4E B2RXH2 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8278411 0.91 ALDH1A1 (0.73) ALDH1A1NPC1RAB9ATDP1GAA
SCHEMBL10293101 0.89 ALDH1A1 (0.62) ALDH1A1NPC1RAB9ATDP1GAA
SCHEMBL8277015 0.89 GAA (0.74) ALDH1A1NPC1RAB9ATDP1GAA
SCHEMBL8277025 0.87 TDP1 (0.61) ALDH1A1NPC1RAB9ATDP1GAA
SCHEMBL8276951 0.86 NPC1 (0.64) ALDH1A1NPC1RAB9ATDP1GAA
SCHEMBL26603347 0.78 ALDH1A1 (0.81) ALDH1A1NPC1RAB9AGAAHPGD
SCHEMBL10293143 0.77 TDP1 (0.60) ALDH1A1NPC1RAB9ATDP1GAA
SCHEMBL1155893 0.77 TDP1 (0.71) ALDH1A1NPC1RAB9ATDP1GAA
SCHEMBL12878913 0.77 TDP1 (0.71) ALDH1A1NPC1RAB9ATDP1GAA
SCHEMBL1158863 0.77 TDP1 (0.71) ALDH1A1NPC1RAB9ATDP1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8211935-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-03 US disclosed
US-20110178061-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-21 US disclosed
US-7888384-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-02-15 US disclosed
US-7888384-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-02-15 US disclosed
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2009-10-08 US disclosed
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2009-10-08 US disclosed
US-7569604-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-08-04 US disclosed
US-7569604-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS CACNA1D, ORAI1, CACNA1C ALDH1A1 3826/4885NPC1 1567/4885RAB9A 1541/4885
US-20110178061-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS CACNA1D, ORAI1, CACNA1C ALDH1A1 3826/4885NPC1 1567/4885RAB9A 1541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.